Yesterday positive results from phase 2 study of their oral vaccine against flu was released. Seeking alpha: The vaccine elicited a significant expansion of mucosal homing receptor alfa4beta7+ (beta7+) plasmablasts, cells that play a key role in an immune response, to about 60% of all activated B cells, significantly higher than 20% from Sanofi's (NYSE:SNY) Fluzone.